

# *Evolut FX+ Implantation With a Protruding Left Main Coronary Stent*

Stephane Noble, MD



**UNIVERSITÉ  
DE GENÈVE**

**FACULTÉ DE MÉDECINE**

# Disclosure of Relevant Financial Relationships

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

## Nature of Financial Relationship

Grant/Research Support

Consultant Fees/Honoraria

## Ineligible Company

Abbott Vascular, Edwards  
LifeSciences

Medtronic, Edwards LifeSciences,  
Abbott Vascular, Abiomed, Cordis

# Clinical Presentation


## Case Demographics




Age (years): 87  
Gender: female  
BMI (kg/m<sup>2</sup>): 17.8

STS score. : 4.69%  
EuroScore II : 4.13%


- She was known for a **3-vx CAD** with an **LM stenting 5 months ago** and an **ostial RCA stenting 2 months later** in the context of **SOB and angina**
- Still symptomatic (SOB)
- **TTE: severe aortic stenosis**



**Mean gradient 39 mmHg, max V: 4.1 m/s, VA: 0.8 cm<sup>2</sup>**



Stent implantation after rotational atherectomy




## ***LAD and left main stenting***


***LAD stent: 3.0x38 mm  
and LM stent 3.5x28 mm***



Spider view



LAO cranial View




***Angiographic control of the left main stent***





RCA stents: 4.0x38 mm and 4.5x24 mm



Annulus Area	457.3 mm <sup>2</sup>
Area Derived Diameter	24.1 mm
Annulus Perimeter	79.8 mm
Perimeter Derived Diameter	25.4 mm
Annulus Min Diameter	19.2 mm
Annulus Max Diameter	28.7 mm





Sinus of Valsalva Diameter	28.7 mm
Sinotubular Junction Diameter	25.0 mm
LCA Height	11.3 mm
RCA Height	12.6 mm
Sinotubular Junction Height	22.3 mm



## Pre-TAVR CT scan

Showing the  
protruding LM stent  
(geographic mismatch)

## Risk of stent crushing with a balloon expandable THV (26 mm, area 4.6 mm<sup>2</sup>)



**FX+ has 3 large cells at 120-degree apart**

## **Large cell size for the different FX+ sizes**

For the 23 mm FX+ :  $30 - 13 = 17 \text{ mm} - 27.6 \text{ F}$   
26 mm :  $28 - 13 = 15 \text{ mm} - 21.0 \text{ F}$   
**29 mm :  $29 - 14 = 15 \text{ mm} - 21.6 \text{ F}$**   
34 mm :  $30 - 14 = 16 \text{ mm} - 23.4 \text{ F}$

Normal cells 3.3 mm – 10F


LM ostium height : 11.3 mm

RCA ostium height : 12.6 mm




*to center the large cell with*

**LM :  $21 - 5 - 11.3 = 10.2 \text{ mm}$  into the LVOT**

**RCA:  $21.5 - 12.6 = 8.9 \text{ mm}$  into the LVOT**










→ **Planning: 29mm Evolut FX + (79.8 mm) positioned > 3 mm (14-11 mm) in the LVOT with optimal commissural alignment**

*to center the large cell with the LM: 10.2 mm, RCA: 8.9 mm*

*In the CO projection: Hat marker at the central-front position  
The 2 dots superimposed*





*Post-TAVR CT scan showing the large cell in front of the off-axis protruding LM stent.*

*The RCA ostium seems adequately positioned in the 3D reconstruction, with no contact with the valve frame, but mildly misaligned with calcium on the axial view*

# Take-home Messages

- Coronary ostia stenting remains a challenge, with a risk of geographic mismatch and subsequent potential longitudinal stent deformation in the case of stent protrusion
- Stent protrusion may complicate a potential future TAVI procedure
- The Evolut FX+ THV offers an interesting option to limit the risk of longitudinal stent deformation while positioning the large cell in front of the ostium
- The rate of commissural alignment using the CO technique exceeds 90% with the Evolut FX platform
- The absence of severe coronary misalignment assessed by CT scan was > 92% in the Optimize PRO TAVR Evolut FX Addendum study

JACC: CARDIOVASCULAR INTERVENTIONS  
© 2023 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN  
COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER  
THE CC BY-NC-ND LICENSE (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)


VOL. 18, NO. 16, 2023

## ORIGINAL RESEARCH

### STRUCTURAL

30-Day and 1-Year Outcomes From the  
Optimize PRO TAVR Evolut FX  
Addendum Study






תודה  
 Dankie Gracias  
 Спасибо  
 شكرًا  
 Merci Takk  
 Köszönjük Terima kasih  
 Grazie Dziękujemy Děkojame  
 Ďakujeme Vielen Dank Paldies  
 Kiitos Täname teid 谢谢  
**Thank You** Tak  
 感谢您 Obrigado Teşekkür Ederiz  
 Σας ευχαριστούμε 감사합니다  
 Bedankt Дěkujeme vám  
 ありがとうございます  
 Tack









# Take-home Message

- Coronary ostia stenting remains a challenge, with a risk of geographic mismatch and subsequent potential longitudinal stent deformation in the case of stent protrusion
- Different PCI techniques could help avoid this issue

## Optimizing Stent Placement in Aorto-Ostial Lesions

Introducing the New Floating Balloon Technique

Franck Digne, MD, Arthur Darmon, MD, Mohammed Nejari, MD

JACC: CARDIOVASCULAR INTERVENTIONS VOL. 17, NO. 17, 2024

SEPTEMBER 9, 2024:2082-2084

## IVUS Guided Ostial Lesion Preparation With Sequential Cutting Balloon Inflations and Stent Placement—The ORCAS Technique

Claudiu Ungureanu<sup>1</sup> | Mihai Cocol<sup>2</sup> | Marouane Boukhris<sup>3</sup> | Giuseppe Colletti<sup>4</sup> | Adrien Jossart<sup>1</sup> | Quentin Trefols<sup>1</sup> | Gregor Leibundgut<sup>5</sup>

- Stent protrusion may complicate a potential future TAVI procedure
- The Evolut FX+ THV offers an interesting option to limit the risk of longitudinal stent deformation while positioning the large cell in front of the ostium
- The rate of commissural alignment using the CO technique exceeds 90% with the Evolut FX platform
- The absence of severe coronary misalignment assessed by CT scan was > 92% in the Optimize PRO TAVR Evolut FX Addendum study